 | • レポートコード：QYR2104Z2771 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、血友病遺伝子治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（血友病A、血友病B）、用途別市場規模（血友病A遺伝子治療、血友病B遺伝子治療）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・血友病遺伝子治療の市場動向 ・企業の競争状況、市場シェア ・血友病遺伝子治療の種類別市場規模（血友病A、血友病B） ・血友病遺伝子治療の用途別市場規模（血友病A遺伝子治療、血友病B遺伝子治療） ・血友病遺伝子治療の北米市場規模2016-2027（アメリカ、カナダ） ・血友病遺伝子治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・血友病遺伝子治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・血友病遺伝子治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・血友病遺伝子治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Spark Therapeutics、Ultragenyx、Shire PLC、Sangamo Therapeutics、Bioverativ、BioMarin、uniQure、Freeline Therapeutics） ・結論 |
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
About 80% of them have hemophilia A, which affects the clotting factor VIII. The second most common form, hemophilia B, is due to a deficiency of the clotting factor IX. Several biotechs are racing to launch the first gene therapy for hemophilia. Currently, uniQure in the Netherlands and Spark Therapeutics in the US have the most advanced programs. Spark scored a victory in December when it presented Phase I/II for its candidate SPK-9001. The gene therapy was able to reduce annual bleeding episodes by 97%, as compared to its competitor uniQure’s candidate, AMT-060. However, uniQure has fought back. The company added a modification in its gene therapy that is known to increase clotting activity by 8- to 9- fold. This improved version has already been cleared to start a Phase III clinical trial in both Europe and the US.
Market Analysis and Insights: Global Hemophilia Gene Therapy Market
The global Hemophilia Gene Therapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hemophilia Gene Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hemophilia Gene Therapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hemophilia Gene Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hemophilia Gene Therapy market.
Global Hemophilia Gene Therapy Scope and Market Size
Hemophilia Gene Therapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hemophilia Gene Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Hemophilia A
Hemophilia B
Segment by Application
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemophilia Gene Therapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Hemophilia A
1.2.3 Hemophilia B
1.3 Market by Application
1.3.1 Global Hemophilia Gene Therapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hemophilia A Gene Therapy
1.3.3 Hemophilia B Gene Therapy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hemophilia Gene Therapy Market Perspective (2016-2027)
2.2 Hemophilia Gene Therapy Growth Trends by Regions
2.2.1 Hemophilia Gene Therapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hemophilia Gene Therapy Historic Market Share by Regions (2016-2021)
2.2.3 Hemophilia Gene Therapy Forecasted Market Size by Regions (2022-2027)
2.3 Hemophilia Gene Therapy Industry Dynamic
2.3.1 Hemophilia Gene Therapy Market Trends
2.3.2 Hemophilia Gene Therapy Market Drivers
2.3.3 Hemophilia Gene Therapy Market Challenges
2.3.4 Hemophilia Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemophilia Gene Therapy Players by Revenue
3.1.1 Global Top Hemophilia Gene Therapy Players by Revenue (2016-2021)
3.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Players (2016-2021)
3.2 Global Hemophilia Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hemophilia Gene Therapy Revenue
3.4 Global Hemophilia Gene Therapy Market Concentration Ratio
3.4.1 Global Hemophilia Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemophilia Gene Therapy Revenue in 2020
3.5 Hemophilia Gene Therapy Key Players Head office and Area Served
3.6 Key Players Hemophilia Gene Therapy Product Solution and Service
3.7 Date of Enter into Hemophilia Gene Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hemophilia Gene Therapy Breakdown Data by Type
4.1 Global Hemophilia Gene Therapy Historic Market Size by Type (2016-2021)
4.2 Global Hemophilia Gene Therapy Forecasted Market Size by Type (2022-2027)
5 Hemophilia Gene Therapy Breakdown Data by Application
5.1 Global Hemophilia Gene Therapy Historic Market Size by Application (2016-2021)
5.2 Global Hemophilia Gene Therapy Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Hemophilia Gene Therapy Market Size (2016-2027)
6.2 North America Hemophilia Gene Therapy Market Size by Type
6.2.1 North America Hemophilia Gene Therapy Market Size by Type (2016-2021)
6.2.2 North America Hemophilia Gene Therapy Market Size by Type (2022-2027)
6.2.3 North America Hemophilia Gene Therapy Market Size by Type (2016-2027)
6.3 North America Hemophilia Gene Therapy Market Size by Application
6.3.1 North America Hemophilia Gene Therapy Market Size by Application (2016-2021)
6.3.2 North America Hemophilia Gene Therapy Market Size by Application (2022-2027)
6.3.3 North America Hemophilia Gene Therapy Market Size by Application (2016-2027)
6.4 North America Hemophilia Gene Therapy Market Size by Country
6.4.1 North America Hemophilia Gene Therapy Market Size by Country (2016-2021)
6.4.2 North America Hemophilia Gene Therapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Hemophilia Gene Therapy Market Size (2016-2027)
7.2 Europe Hemophilia Gene Therapy Market Size by Type
7.2.1 Europe Hemophilia Gene Therapy Market Size by Type (2016-2021)
7.2.2 Europe Hemophilia Gene Therapy Market Size by Type (2022-2027)
7.2.3 Europe Hemophilia Gene Therapy Market Size by Type (2016-2027)
7.3 Europe Hemophilia Gene Therapy Market Size by Application
7.3.1 Europe Hemophilia Gene Therapy Market Size by Application (2016-2021)
7.3.2 Europe Hemophilia Gene Therapy Market Size by Application (2022-2027)
7.3.3 Europe Hemophilia Gene Therapy Market Size by Application (2016-2027)
7.4 Europe Hemophilia Gene Therapy Market Size by Country
7.4.1 Europe Hemophilia Gene Therapy Market Size by Country (2016-2021)
7.4.2 Europe Hemophilia Gene Therapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Hemophilia Gene Therapy Market Size (2016-2027)
8.2 Asia-Pacific Hemophilia Gene Therapy Market Size by Type
8.2.1 Asia-Pacific Hemophilia Gene Therapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hemophilia Gene Therapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Application
8.3.1 Asia-Pacific Hemophilia Gene Therapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hemophilia Gene Therapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Hemophilia Gene Therapy Market Size by Region
8.4.1 Asia-Pacific Hemophilia Gene Therapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hemophilia Gene Therapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Hemophilia Gene Therapy Market Size (2016-2027)
9.2 Latin America Hemophilia Gene Therapy Market Size by Type
9.2.1 Latin America Hemophilia Gene Therapy Market Size by Type (2016-2021)
9.2.2 Latin America Hemophilia Gene Therapy Market Size by Type (2022-2027)
9.2.3 Latin America Hemophilia Gene Therapy Market Size by Type (2016-2027)
9.3 Latin America Hemophilia Gene Therapy Market Size by Application
9.3.1 Latin America Hemophilia Gene Therapy Market Size by Application (2016-2021)
9.3.2 Latin America Hemophilia Gene Therapy Market Size by Application (2022-2027)
9.3.3 Latin America Hemophilia Gene Therapy Market Size by Application (2016-2027)
9.4 Latin America Hemophilia Gene Therapy Market Size by Country
9.4.1 Latin America Hemophilia Gene Therapy Market Size by Country (2016-2021)
9.4.2 Latin America Hemophilia Gene Therapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemophilia Gene Therapy Market Size (2016-2027)
10.2 Middle East & Africa Hemophilia Gene Therapy Market Size by Type
10.2.1 Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Application
10.3.1 Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Hemophilia Gene Therapy Market Size by Country
10.4.1 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Spark Therapeutics
11.1.1 Spark Therapeutics Company Details
11.1.2 Spark Therapeutics Business Overview
11.1.3 Spark Therapeutics Hemophilia Gene Therapy Introduction
11.1.4 Spark Therapeutics Revenue in Hemophilia Gene Therapy Business (2016-2021)
11.1.5 Spark Therapeutics Recent Development
11.2 Ultragenyx
11.2.1 Ultragenyx Company Details
11.2.2 Ultragenyx Business Overview
11.2.3 Ultragenyx Hemophilia Gene Therapy Introduction
11.2.4 Ultragenyx Revenue in Hemophilia Gene Therapy Business (2016-2021)
11.2.5 Ultragenyx Recent Development
11.3 Shire PLC
11.3.1 Shire PLC Company Details
11.3.2 Shire PLC Business Overview
11.3.3 Shire PLC Hemophilia Gene Therapy Introduction
11.3.4 Shire PLC Revenue in Hemophilia Gene Therapy Business (2016-2021)
11.3.5 Shire PLC Recent Development
11.4 Sangamo Therapeutics
11.4.1 Sangamo Therapeutics Company Details
11.4.2 Sangamo Therapeutics Business Overview
11.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Introduction
11.4.4 Sangamo Therapeutics Revenue in Hemophilia Gene Therapy Business (2016-2021)
11.4.5 Sangamo Therapeutics Recent Development
11.5 Bioverativ
11.5.1 Bioverativ Company Details
11.5.2 Bioverativ Business Overview
11.5.3 Bioverativ Hemophilia Gene Therapy Introduction
11.5.4 Bioverativ Revenue in Hemophilia Gene Therapy Business (2016-2021)
11.5.5 Bioverativ Recent Development
11.6 BioMarin
11.6.1 BioMarin Company Details
11.6.2 BioMarin Business Overview
11.6.3 BioMarin Hemophilia Gene Therapy Introduction
11.6.4 BioMarin Revenue in Hemophilia Gene Therapy Business (2016-2021)
11.6.5 BioMarin Recent Development
11.7 uniQure
11.7.1 uniQure Company Details
11.7.2 uniQure Business Overview
11.7.3 uniQure Hemophilia Gene Therapy Introduction
11.7.4 uniQure Revenue in Hemophilia Gene Therapy Business (2016-2021)
11.7.5 uniQure Recent Development
11.8 Freeline Therapeutics
11.8.1 Freeline Therapeutics Company Details
11.8.2 Freeline Therapeutics Business Overview
11.8.3 Freeline Therapeutics Hemophilia Gene Therapy Introduction
11.8.4 Freeline Therapeutics Revenue in Hemophilia Gene Therapy Business (2016-2021)
11.8.5 Freeline Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Hemophilia Gene Therapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Hemophilia A
Table 3. Key Players of Hemophilia B
Table 4. Global Hemophilia Gene Therapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Hemophilia Gene Therapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Hemophilia Gene Therapy Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Hemophilia Gene Therapy Market Share by Regions (2016-2021)
Table 8. Global Hemophilia Gene Therapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Hemophilia Gene Therapy Market Share by Regions (2022-2027)
Table 10. Hemophilia Gene Therapy Market Trends
Table 11. Hemophilia Gene Therapy Market Drivers
Table 12. Hemophilia Gene Therapy Market Challenges
Table 13. Hemophilia Gene Therapy Market Restraints
Table 14. Global Hemophilia Gene Therapy Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Hemophilia Gene Therapy Market Share by Players (2016-2021)
Table 16. Global Top Hemophilia Gene Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia Gene Therapy as of 2020)
Table 17. Ranking of Global Top Hemophilia Gene Therapy Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Hemophilia Gene Therapy Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Hemophilia Gene Therapy Product Solution and Service
Table 21. Date of Enter into Hemophilia Gene Therapy Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Hemophilia Gene Therapy Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Hemophilia Gene Therapy Revenue Market Share by Type (2016-2021)
Table 25. Global Hemophilia Gene Therapy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Hemophilia Gene Therapy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Hemophilia Gene Therapy Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Hemophilia Gene Therapy Revenue Market Share by Application (2016-2021)
Table 29. Global Hemophilia Gene Therapy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Hemophilia Gene Therapy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Hemophilia Gene Therapy Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Hemophilia Gene Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Hemophilia Gene Therapy Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Hemophilia Gene Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Hemophilia Gene Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Hemophilia Gene Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Hemophilia Gene Therapy Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Hemophilia Gene Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Hemophilia Gene Therapy Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Hemophilia Gene Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Hemophilia Gene Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Hemophilia Gene Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Hemophilia Gene Therapy Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Hemophilia Gene Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Hemophilia Gene Therapy Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Hemophilia Gene Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Hemophilia Gene Therapy Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Hemophilia Gene Therapy Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Hemophilia Gene Therapy Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Hemophilia Gene Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Hemophilia Gene Therapy Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Hemophilia Gene Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Hemophilia Gene Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Hemophilia Gene Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 61. Spark Therapeutics Company Details
Table 62. Spark Therapeutics Business Overview
Table 63. Spark Therapeutics Hemophilia Gene Therapy Product
Table 64. Spark Therapeutics Revenue in Hemophilia Gene Therapy Business (2016-2021) & (US$ Million)
Table 65. Spark Therapeutics Recent Development
Table 66. Ultragenyx Company Details
Table 67. Ultragenyx Business Overview
Table 68. Ultragenyx Hemophilia Gene Therapy Product
Table 69. Ultragenyx Revenue in Hemophilia Gene Therapy Business (2016-2021) & (US$ Million)
Table 70. Ultragenyx Recent Development
Table 71. Shire PLC Company Details
Table 72. Shire PLC Business Overview
Table 73. Shire PLC Hemophilia Gene Therapy Product
Table 74. Shire PLC Revenue in Hemophilia Gene Therapy Business (2016-2021) & (US$ Million)
Table 75. Shire PLC Recent Development
Table 76. Sangamo Therapeutics Company Details
Table 77. Sangamo Therapeutics Business Overview
Table 78. Sangamo Therapeutics Hemophilia Gene Therapy Product
Table 79. Sangamo Therapeutics Revenue in Hemophilia Gene Therapy Business (2016-2021) & (US$ Million)
Table 80. Sangamo Therapeutics Recent Development
Table 81. Bioverativ Company Details
Table 82. Bioverativ Business Overview
Table 83. Bioverativ Hemophilia Gene Therapy Product
Table 84. Bioverativ Revenue in Hemophilia Gene Therapy Business (2016-2021) & (US$ Million)
Table 85. Bioverativ Recent Development
Table 86. BioMarin Company Details
Table 87. BioMarin Business Overview
Table 88. BioMarin Hemophilia Gene Therapy Product
Table 89. BioMarin Revenue in Hemophilia Gene Therapy Business (2016-2021) & (US$ Million)
Table 90. BioMarin Recent Development
Table 91. uniQure Company Details
Table 92. uniQure Business Overview
Table 93. uniQure Hemophilia Gene Therapy Product
Table 94. uniQure Revenue in Hemophilia Gene Therapy Business (2016-2021) & (US$ Million)
Table 95. uniQure Recent Development
Table 96. Freeline Therapeutics Company Details
Table 97. Freeline Therapeutics Business Overview
Table 98. Freeline Therapeutics Revenue in Hemophilia Gene Therapy Business (2016-2021) & (US$ Million)
Table 99. Freeline Therapeutics Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hemophilia Gene Therapy Market Share by Type: 2020 VS 2027
Figure 2. Hemophilia A Features
Figure 3. Hemophilia B Features
Figure 4. Global Hemophilia Gene Therapy Market Share by Application: 2020 VS 2027
Figure 5. Hemophilia A Gene Therapy Case Studies
Figure 6. Hemophilia B Gene Therapy Case Studies
Figure 7. Hemophilia Gene Therapy Report Years Considered
Figure 8. Global Hemophilia Gene Therapy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Hemophilia Gene Therapy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Hemophilia Gene Therapy Market Share by Regions: 2020 VS 2027
Figure 11. Global Hemophilia Gene Therapy Market Share by Regions (2022-2027)
Figure 12. Global Hemophilia Gene Therapy Market Share by Players in 2020
Figure 13. Global Top Hemophilia Gene Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia Gene Therapy as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Hemophilia Gene Therapy Revenue in 2020
Figure 15. Global Hemophilia Gene Therapy Revenue Market Share by Type (2016-2021)
Figure 16. Global Hemophilia Gene Therapy Revenue Market Share by Type (2022-2027)
Figure 17. North America Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Hemophilia Gene Therapy Market Share by Type (2016-2027)
Figure 19. North America Hemophilia Gene Therapy Market Share by Application (2016-2027)
Figure 20. North America Hemophilia Gene Therapy Market Share by Country (2016-2027)
Figure 21. United States Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Hemophilia Gene Therapy Market Share by Type (2016-2027)
Figure 25. Europe Hemophilia Gene Therapy Market Share by Application (2016-2027)
Figure 26. Europe Hemophilia Gene Therapy Market Share by Country (2016-2027)
Figure 27. Germany Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Hemophilia Gene Therapy Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Hemophilia Gene Therapy Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Hemophilia Gene Therapy Market Share by Region (2016-2027)
Figure 37. China Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Hemophilia Gene Therapy Market Share by Type (2016-2027)
Figure 45. Latin America Hemophilia Gene Therapy Market Share by Application (2016-2027)
Figure 46. Latin America Hemophilia Gene Therapy Market Share by Country (2016-2027)
Figure 47. Mexico Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Hemophilia Gene Therapy Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Hemophilia Gene Therapy Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Hemophilia Gene Therapy Market Share by Country (2016-2027)
Figure 53. Turkey Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Hemophilia Gene Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Spark Therapeutics Revenue Growth Rate in Hemophilia Gene Therapy Business (2016-2021)
Figure 57. Ultragenyx Revenue Growth Rate in Hemophilia Gene Therapy Business (2016-2021)
Figure 58. Shire PLC Revenue Growth Rate in Hemophilia Gene Therapy Business (2016-2021)
Figure 59. Sangamo Therapeutics Revenue Growth Rate in Hemophilia Gene Therapy Business (2016-2021)
Figure 60. Bioverativ Revenue Growth Rate in Hemophilia Gene Therapy Business (2016-2021)
Figure 61. BioMarin Revenue Growth Rate in Hemophilia Gene Therapy Business (2016-2021)
Figure 62. uniQure Revenue Growth Rate in Hemophilia Gene Therapy Business (2016-2021)
Figure 63. Freeline Therapeutics Revenue Growth Rate in Hemophilia Gene Therapy Business (2016-2021)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
世界の血友病A・B組換え因子補充療法市場規模・現状・予測（2021年-2027年） Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptom…- 世界の後天性血友病A治療市場規模・現状・予測（2021年-2027年） ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. Market Analysis and Insights: Global Acquired hemophilia A Treatment Market The global Acquired hemophilia A Treatment market size is projected to reach US$ X…
- 世界の血友病治療市場 2021：企業別、地域別、種類・用途別 The Hemophilia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulation…
- 世界の血友病治療市場規模・現状・予測（2021年-2027年） Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. These proteins work with platelets i.e. small blood cell fragments that form in the bone marr…
- 世界の血友病治療市場規模・現状・予測（2021年-2027年） Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. These proteins work with platelets i.e. small blood cell fragments that form in the bone marr…